Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $56

Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $69 to $56.